NTX 2R13
Alternative Names: NTX-2R13Latest Information Update: 05 Jan 2023
At a glance
- Originator Nectin Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD112 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Jan 2023 Nectin Therapeutics plans to file IND for Solid tumours in 2023 (Nectin Therapeutics pipeline, January 2023)
- 10 Mar 2022 Preclinical trials in Solid tumours in USA (Parenteral) (Nectin Therapeutics pipeline, March 2022)